Current status of radioimmunotherapy.

[1]  R Mohan,et al.  Three-dimensional dosimetry for radioimmunotherapy treatment planning. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Larson,et al.  Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  M. Andreeff,et al.  Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Larson.  A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen. , 1993, Cancer investigation.

[5]  D. Scheinberg,et al.  Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. , 1992, Cancer research.

[6]  M. Kaminski,et al.  Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Vanderheyden,et al.  Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  H. Nabi,et al.  Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. , 1992, American journal of surgery.

[9]  D. Scheinberg,et al.  Chimeric and humanized antibodies with specificity for the CD33 antigen. , 1992, Journal of immunology.

[10]  S. Larson,et al.  Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  S. Order,et al.  Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Scheinberg,et al.  A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Larson,et al.  Tumor Targeting with Radiolabeled Antibody for Diagnosis and Therapy , 1991, Immunology and Allergy Clinics of North America.

[14]  J. Schlom,et al.  In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[15]  J. Eary,et al.  Radiolabeled antibody therapy of human B cell lymphomas. , 1991, Advances in experimental medicine and biology.

[16]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R Mohan,et al.  Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  I. Bernstein,et al.  Imaging and treatment of B-cell lymphoma. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  S. Larson,et al.  Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. , 1990, Cancer research.

[20]  H. Kalofonos,et al.  Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. Eary,et al.  Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Sullivan,et al.  Intraperitoneal radioimmunotherapy for ovarian cancer , 1989 .

[23]  T. Zhao-you,et al.  Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. , 1989 .

[24]  S. Larson,et al.  Tumor targeting with monoclonal antibody B72.3. , 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[25]  D. Snook,et al.  Intraperitoneal 131I‐ and 90‐labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry , 1988 .

[26]  S. Adelstein,et al.  Intracellular Localisation of Auger Electron Emitters: Biophysical Dosimetry , 1985 .

[27]  D. Ettinger,et al.  Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Taylor‐Papadimitriou,et al.  Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment. A report from the Hammersmith Oncology Group and the Imperial Cancer Research Fund. , 1984, The Lancet.

[29]  S. Larson,et al.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. , 1984, Cancer treatment reports.

[30]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[31]  W. Dewey,et al.  131I‐labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials , 1967, Cancer.

[32]  D. Pressman,et al.  The in vivo localization of anti‐Wagner‐osteogenic‐sarcoma antibodies , 1953, Cancer.